ストックスクリーナーアプリを入手
0.0002
42.86%
-0.00015
前日終値:
$0.00035
開ける：
$0.0002
24時間の取引高:
22,225
Relative Volume:
2.68
時価総額：
$N/A
収益：
$386.00K
当期純損益:
$-97.82M
株価収益率:
-0.000066
EPS:
-3.0311
ネットキャッシュフロー:
$-100.06M
1週間 パフォーマンス:
-42.86%
1か月 パフォーマンス:
-42.86%
6か月 パフォーマンス:
-96.00%
1年 パフォーマンス:
-99.50%
1日の値動き範囲:
$0.0002
$0.0002
1週間の範囲:
$0.0002
$0.0002
52週間の値動き範囲:
$0.0002
$0.0282
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Compare SYRS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.0002 | 0 | 386.00K | -97.82M | -100.06M | -3.0311 |
VRTX
Vertex Pharmaceuticals Inc
|
450.85 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
719.44 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
817.17 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.76 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
314.04 | 32.24B | 5.36B | 287.73M | 924.18M | 2.5229 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-11-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-09-22 | 開始されました | Alliance Global Partners | Buy |
| 2020-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-03-08 | 再開されました | JMP Securities | Mkt Outperform |
| 2019-02-14 | 再開されました | Oppenheimer | Outperform |
| 2018-11-05 | アップグレード | ROTH Capital | Neutral → Buy |
| 2018-03-13 | 繰り返されました | Wedbush | Outperform |
| 2017-10-31 | 再開されました | Piper Jaffray | Overweight |
| 2017-10-23 | 開始されました | ROTH Capital | Neutral |
| 2017-08-10 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
すべてを表示
Syros Pharmaceuticals Inc (SYRS) 最新ニュース
MSN Money - MSN
Acute Myeloid Leukemia Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma, Syros Pharma, TC Biopharm - Barchart.com
hVIVO plc (OPORF) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Syros Pharmaceuticals, Inc. (0LC7.L) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Stock List: Research Stocks from Around the World - GuruFocus
Polaris Management Co VII L L C Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Syros Pharmaceuticals (SYRS) Expected to Announce Quarterly Earnings on Wednesday - Defense World
MSN - MSN
Myelodysplastic Syndrome Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Globe and Mail
Reviewing Vectura Group (OTCMKTS:VEGPF) and Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Syros to delist from Nasdaq, deregister from SEC - MSN
AKPKD Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeut - The Globe and Mail
Myelodysplastic Syndrome Pipeline Analysis, 2025 by DelveInsight | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, - Barchart.com
Syros Pharmaceuticals, Inc. (SYRS) stock price, news, quote and history - Yahoo Finance Singapore
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital - Yahoo Finance
Syros Pharmaceuticals (SYRS) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Syros Pharmaceuticals(SYRS) Stock Options Chain | Quotes & News - Moomoo
SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire
SYRS Stock Price, News & Analysis - Stock Titan
Rege Nephro Acquires Tamibarotene Assets from Syros Pharmaceuticals to Advance ADPKD Program - BioPharma APAC
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - ChartMill
SYRS Stock Price and Chart — OTC:SYRS - TradingView
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com
Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), State Street SPDR S&P 500 ETF Trust (ARCA:SPY) - Benzinga
Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations - Stock Titan
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - MSN
Syros Pharmaceuticals stock plunges to 52-week low of $0.16 - Investing.com
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Investors to Inquire about Securities Investigation - ACCESS Newswire
Odyssey hires Jason Haas as CFO - BioCentury
Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com
BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President - Business Wire
Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com Australia
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros Pharmaceuticals announces major company changes - Investing.com
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - gurufocus.com
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - Yahoo Finance
JMP Securities Downgrades Syros Pharmaceuticals(SYRS.US) to Hold Rating - Moomoo
TD Cowen Downgrades Syros Pharmaceuticals(SYRS.US) to Hold Rating - Moomoo
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - Insider Monkey
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update - BioSpace
Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - PR Newswire
The market is buzzing with gapping stocks on Friday. Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS) By GuruFocus - Investing.com Canada
Syros Pharmaceuticals, Inc. (SYRS) Investigation: - GlobeNewswire
Syros Pharmaceuticals Inc (SYRS) 財務データ
収益
当期純利益
現金流量
EPS
1.76%
1.01%
大文字化:
|
ボリューム (24 時間):